Last 58,200 KRW
Change Today -100.00 / -0.17%
Volume 34.1K
069620 On Other Exchanges
Korea SE
As of 1:17 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

daewoong pharmaceutical co (069620) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/26/14 - 79,400
52 Week Low
06/5/14 - 54,500
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAEWOONG PHARMACEUTICAL CO (069620)

Related News

No related news articles were found.

daewoong pharmaceutical co (069620) Related Businessweek News

No Related Businessweek News Found

daewoong pharmaceutical co (069620) Details

Daewoong Pharmaceutical Co., Ltd. manufactures and sells prescription drugs in South Korea and internationally. The company offers various drugs, including anti-anemic agents, anti-diabetic agents, anti-histamine agents, anti-microbials, anti-neoplastics, anti-obesity agents, anti-osteoporotic agents, biosimilar products, bone and joint diseases, bone grafting materials, cardiovascular drugs, central nervous system drugs, circulatory system agents, and dermatologic products and agents. It also provides dermatology products, gastrointestinal products and agents, health and nutrient supplements, healthcare products, hepatobiliary activators, infection and respiratory products, medical devices and quasi drugs, drugs for metabolic diseases, neuropsychotis drugs, nutraceuticals, oncology drugs, respiratory system agents, skeletal muscle relaxants, urological agents, and wound healing products, as well as anti-pyretic, analgesic, anti-inflammatory agents. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Founded in 1945

daewoong pharmaceutical co (069620) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daewoong pharmaceutical co (069620) Key Developments

Daewoong Pharmaceutical Announces Approval of Eklira Genuair for COPD

South Korea's Ministry of Food and Drug Safety (MFDS) has approved an application by local firm Daewoong Pharmaceutical to market Eklira Genuair (aclidinium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The approval was based on a Phase III clinical trial conducted by Daewoong in 20 hospitals in South Korea. Daewoong is likely to launch Eklira Genuair during the first half of 2015, once it has been given a National Health Insurance (NHI) price listing.

Daewoong Bio Mulls Overseas Acquisition

Daewoong Pharmaceutical Co., Ltd. (KOSE:A069620) said on May 23, 2014, that its affiliate Daewoong Bio Inc. is seeking to acquire a company overseas, an answer requested by the Korea Exchange to the rumors that the company is considering acquisition of a European company. Daewoong Pharm said Daewoong Bio has considered overseas M&As to diversify its business into new markets in Europe and elsewhere, but nothing has been decided yet.

Daewoong Pharmaceutical Co., Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014

Daewoong Pharmaceutical Co., Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 . Venue: Kempinski Hotel Suzhou, Suzhou, China.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
069620:KS 58,200.00 KRW -100.00

069620 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 069620.
View Industry Companies

Industry Analysis


Industry Average

Valuation 069620 Industry Range
Price/Earnings 18.5x
Price/Sales 0.8x
Price/Book 1.3x
Price/Cash Flow 18.1x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEWOONG PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at